| Bioactivity | mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition[1]. |
| Name | mDPR-Val-Cit-PAB-MMAE TFA |
| CAS | 2185872-76-6 |
| Formula | C67H101F3N12O17 |
| Molar Mass | 1403.58 |
| Appearance | 固体 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. Moquist, et al. Preparation of drug conjugates of IgG1 antibodies with self-stabilizing linkers having improved physiochemical properties for treating cancers and autoimmune diseases. World Intellectual Property Organization, WO2018031690 A1. 2018-02-15. |
mDPR-Val-Cit-PAB-MMAE TFA
CAS: 2185872-76-6 F: C67H101F3N12O17 W: 1403.58
mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin p
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.